After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences' magrolimab, the centre piece of its $4.9 billion acquisition of Forty Seven in 2020.

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets. Gilead ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

Following this transaction, Dickinson holds 129,873 shares of Gilead Sciences. The sale was made under a Rule 10b5-1 trading plan, which was adopted on August 29, 2024.

The mission of the Department of Physical Geography is to be at the forefront of research in Earth Surface Dynamics. Our knowledge and understanding of Earth’s continental and coastal systems ...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the ...

Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

(Reuters) - Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases. The Danish company will ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...